Cover Image

Manipulating the gut microbiome to alleviate steatotic liver disease: current progress and challenges

The prevalence of metabolic-dysfunction-associated steatotic liver disease (MASLD) is alarmingly high; it is estimated to affect up to a quarter of the global population, making it the most common liver disorder worldwide. MASLD is characterized by excessive hepatic fat accumulation and is commonly...

Full description

Saved in:
Bibliographic Details
Main Authors: Saenz, Ernesto (Author) , Montagut, Nathally Espinosa (Author) , Wang, Baohong (Author) , Stein-Thöringer, Christoph (Author) , Wang, Kaicen (Author) , Weng, Honglei (Author) , Ebert, Matthias (Author) , Schneider, Kai Markus (Author) , Li, Lanjuan (Author) , Teufel, Andreas (Author)
Format: Article (Journal)
Language:English
Published: September 2024
In: Engineering
Year: 2024, Volume: 40, Pages: 51-60
ISSN:2096-0026
DOI:10.1016/j.eng.2024.03.019
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.eng.2024.03.019
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2095809924002686
Get full text
Author Notes:Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel
Description
Summary:The prevalence of metabolic-dysfunction-associated steatotic liver disease (MASLD) is alarmingly high; it is estimated to affect up to a quarter of the global population, making it the most common liver disorder worldwide. MASLD is characterized by excessive hepatic fat accumulation and is commonly associated with comorbidities such as obesity, dyslipidemia, and insulin resistance; however, it can also manifest in lean individuals. Therefore, it is crucial to develop effective therapies for this complex condition. Currently, there are no approved medications for MASLD treatment, so there is a pressing need to investigate alternative approaches. Extensive research has characterized MASLD as a multifaceted disease, frequently linked to metabolic disorders that stem from dietary habits. Evidence suggests that changes in the gut microbiome play a fundamental role in the development and progression of MASLD from simple steatosis to steatohepatitis and even hepatocellular carcinoma (HCC). In this review, we critically examine the literature on the emerging field of gut-microbiota-based therapies for MASLD and metabolic-dysfunction-associated steatohepatitis (MASH), including interventions such as fecal microbiota transplantation (FMT), probiotics, prebiotics, short-chain fatty acids, antibiotics, metabolic pathway targeting, and immune checkpoint kinase blockade.
Item Description:Online veröffentlicht: 31. Mai 2024, Artikelversion: 13. September 2024
Gesehen am 23.10.2024
Physical Description:Online Resource
ISSN:2096-0026
DOI:10.1016/j.eng.2024.03.019

Similar Items